Form 4: Axogen Executive Angelo Scopelianos Reports Stock Transactions

Angelo Scopelianos, Chief R&D Officer of Axogen, Inc., reports the vesting and sale of restricted stock units to cover tax obligations.

Summary

• On March 16, 2024, Angelo Scopelianos vested 21,281, 4,125, and 2,500 restricted stock units.
• On March 21, 2024, Scopelianos sold 5,251, 1,020, and 610 shares of common stock at $7.68 per share.
• These sales were to cover tax withholding obligations related to the vesting of the restricted stock units.
• Following these transactions, Scopelianos beneficially owns 57,994 shares of Axogen common stock.
• The restricted stock units vest over a period of four years from the grant date, with varying vesting schedules.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock transactions by an executive. It doesn't inherently convey positive or negative sentiment about the company's performance or future prospects.

Positives

• The vesting of restricted stock units indicates that Scopelianos is meeting the vesting requirements set by the company.
• The 'sell to cover' transaction ensures that tax obligations are met without requiring Scopelianos to use personal funds.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to monitor potential alignment of interests between management and shareholders.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they involve the sale of shares by an executive to cover tax obligations.

Key Dates